Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours

Endocrine-Related Cancer

Volumn 13, Issue 4, 2006, Pages 1203-1211

  Gotthardt, Martin ^a   Béhé, Martin P ^b   Grass, Julia ^b   Bauhofer, Artur ^b   Rinke, Anja ^b   Schipper, Meike L ^b   Kalinowski, Marc ^b   Arnold, Rudolf ^b   Oyen, Wim J G ^a   Behr, Thomas M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ B RECEPTOR; GASTRIN RECEPTOR; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; BRONCHUS CARCINOID; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARAGANGLIOMA; PROTEIN BINDING; PROTEIN EXPRESSION; SCINTIGRAPHY; TUMOR LOCALIZATION;

ADULT; AGED; CARCINOID TUMOR; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUCAGONOMA; HUMANS; INDIUM RADIOISOTOPES; INSULINOMA; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PARAGANGLIOMA; PENTETIC ACID; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, SOMATOSTATIN;

EID: 33846820574     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01245     Document Type: Article

References (24)

1. 111In-DTPA-D-PHE]-Octreotide for detection of somatostatin receptor-positive tumours in rats. Life Science 49 1593-1601.
2. Behe M, Kluge G, Becker W, Gotthardt M & Behr TM 2005 Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. Journal of Nuclear Medicine 46 1012-1015.
3. Behr TM, Jenner M, Béhé M, Angerstein C, Gratz S, Raue F & Becker W 1999a Radiolabelled peptides for targeting of cholecystokinin-B/gastrin receptor expressing tumours: from preclinical development to initial clinical results. Journal of Nuclear Medicine 40 1029-1044.
4. Behr TM, Behe M, Angerstein C, Gratz S, Mach R, Hagemann L, Jenner N, Stiehler M, Frank-Raue K, Raue F & Becker W 1999b Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clinical Cancer Research 5 3124s-3138s.
5. Blum J, Handmaker H, Lister-James J & Rinne N 2000 A multi-center trial with a somatostatin analog 99mTc-depreotide in the evaluation solitary pulmonary nodules. Chest 117 1232-1238.
6. 111In- labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. European Journal of Nuclear Medicine and Molecular Imaging 30 1134-1139.
7. 111In-labelled octreotide derivatives. European Journal of Nuclear Medicine 27 1318-1325.
8. Gotthardt M, Boermann OC, Behr TM, Béhé MP & Oyen WJG 2004 Development and clinical application of peptide-based radiopharmaceuticals. Current Pharmaceutical Design 10 2951-2963.
9. Gotthardt M, Béhé M, Beuter D, Battmann A, Bauhofer A, Schurrat T, Schipper M, Pollum H, Oyen WJG, Behr TM 2006 Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging (in press).
10. Grewal RK, Dadparvar S, Yu JQ, Babaria CJ, Cavanaugh T, Sherman M & Jacobstein J 2002 Efficacy of 99mTc-depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer Journal 8 400-404.
11. Hessenius C, Bäder M, Meinhold H, Bohmig M, Faiss S, Reubi JC & Wiedenmann B 2000 Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. European Journal of Nuclear Medicine 27 1684-1693.
12. Janssen ML, Oyen WJG, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, Rajopadhye M, Boonstra H, Corstens FH & Boerman OC 2002 Tumour targeting with radiolabelled αvβ3 integrin binding peptides in a nude mouse model. Cancer Research 62 6146-6151.
13. Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, Kamal T & Goldenberg DM 1996 Improved detection of medullary thyroid cancer with radiolabelled antibodies to carcinoembryonic antigen. Journal of Clinical Oncology 14 1209-1217.
14. 123I-Tyr3)-Octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 20 716-731.
15. Lamberts SW, Bakker WH, Reubi JC & Krenning EP 1990 Somatostatin-receptor imaging in the localization of endocrine tumours. New England Journal of Medicine 323 1246-1249.
16. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, Mignon M & le Guludec D 1997 Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumours. Journal of Nuclear Medicine 38 853-858.
17. Modlin IM & Tang LH 1997 Approaches to the diagnosis of gut neuroendocrine tumours: the last word today. Gastroenterology 112 583-590.
18. Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S & Munz DL 1998 Somatostatin receptor scintigraphy in small cell lung cancer: results of a multicenter study. Journal of Nuclear Medicine 39 224-227.
19. Reubi JC & Waser B 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor imaging. European Journal of Nuclear Medicine and Molecular Imaging 30 781-793.
20. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS & Macke HR 2000 Affinity profiles for human somatostatin receptor subtypes sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. European Journal of Nuclear Medicine and Molecular Imaging 27 273-282.
21. Ricke J, Klose KJ, Mignon M, Öberg K & Wiedenmann B 2001 Standardisation of imaing in neuroendocrine tumours: results of a European Delphi process. European Journal of Radiology 37 8-17.
22. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, Sutliff VE & Jensen RT 1997 Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 112 335-347.
23. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W & Valent P 1994 Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumours. New England Journal of Medicine 331 1116-1121.
24. 111In- and 90Y-DOTA-Lanreotide: results an implications of the MAURITIUS trial. Seminars in Nuclear Medicine 32 148-155.